SG52568A1 - Method of tumor treatment - Google Patents

Method of tumor treatment

Info

Publication number: SG52568A1
Authority: SG; Singapore
Prior art keywords: administering; tumors; treatment; mammal; formula
Prior art date: 1993-09-22

Application number

SG1996006227A

Other languages

English (en)

Inventor

Martin J Brown

Original Assignee

Univ Leland Stanford Junior

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-22

Filing date

1994-09-19

Publication date

1998-09-28

1994-09-19 Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior

1998-09-28 Publication of SG52568A1 publication Critical patent/SG52568A1/en

Links

206010028980 Neoplasm Diseases 0.000 title abstract 6
238000000034 method Methods 0.000 title abstract 2
BNZPFJBUHRBLNB-UHFFFAOYSA-N 1-oxido-1,2,4-benzotriazin-1-ium Chemical compound C1=CC=C2[N+]([O-])=NC=NC2=C1 BNZPFJBUHRBLNB-UHFFFAOYSA-N 0.000 abstract 3
241000124008 Mammalia Species 0.000 abstract 2
239000012829 chemotherapy agent Substances 0.000 abstract 2
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SG1996006227A 1993-09-22 1994-09-19 Method of tumor treatment SG52568A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/125,609 US5484612A (en)	1993-09-22	1993-09-22	Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin

Publications (1)

Publication Number	Publication Date
SG52568A1 true SG52568A1 (en)	1998-09-28

Family

ID=22420569

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG1996006227A SG52568A1 (en)	1993-09-22	1994-09-19	Method of tumor treatment

Country Status (22)

Country	Link
US (4)	US5484612A (de)
EP (2)	EP0649658B1 (de)
JP (1)	JPH07215882A (de)
KR (1)	KR100383402B1 (de)
AT (2)	ATE270553T1 (de)
AU (1)	AU690132B2 (de)
CA (1)	CA2132578C (de)
CZ (1)	CZ289742B6 (de)
DE (2)	DE69424915T2 (de)
DK (2)	DK0649658T3 (de)
ES (2)	ES2224517T3 (de)
GR (1)	GR3034360T3 (de)
HU (1)	HUT71119A (de)
IL (1)	IL111025A (de)
MY (1)	MY112405A (de)
NO (1)	NO943524L (de)
NZ (2)	NZ264502A (de)
PT (2)	PT649658E (de)
RU (1)	RU2148406C1 (de)
SG (1)	SG52568A1 (de)
SK (1)	SK282178B6 (de)
UA (1)	UA49787C2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5597582A (en) *	1995-09-12	1997-01-28	Sanofi	Oral gel capsule formulation of 1,2,4-benzotriazine oxides
US5672702A (en) *	1995-12-04	1997-09-30	Sanofi	Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide
AU6178198A (en) *	1997-03-07	1998-09-22	Sanofi Pharmaceuticals, Inc.	Method of treating a tumor
US6103698A (en)	1997-03-13	2000-08-15	Basf Aktiengesellschaft	Dolastatin-15 derivatives in combination with taxanes
ATE439137T1 (de) *	1997-11-14	2009-08-15	Gen Hospital Corp	Behandlung von hämatologischen störungen
US6074626A (en) *	1998-03-20	2000-06-13	Molecular Radiation Management, Inc.	Radioactive cisplatin in the treatment of cancer
US6620382B1 (en) *	1998-05-22	2003-09-16	Biopheresis Technologies, Llc.	Method and compositions for treatment of cancers
US6819761B1 (en) *	1999-09-16	2004-11-16	Silicon Laboratories, Inc.	Programmable constant current “off hook” circuit
CA2385528C (en)	1999-10-01	2013-12-10	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU2169301A (en)	1999-12-21	2001-07-03	Ufz-Umweltforschungszentrum Leipzig-Halle Gmbh	Novel 3-substituted 1,2,4-benzotriazines, a method for their production and the use thereof
US6989139B2 (en) *	2000-02-15	2006-01-24	Bristol-Myers Squibb Pharma Company	Matrix metalloproteinase inhibitors
AUPQ641100A0 (en) *	2000-03-23	2000-04-15	Australia Nuclear Science & Technology Organisation	Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
CA2307278A1 (en) *	2000-04-28	2001-10-28	University Of British Columbia	Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US6338859B1 (en) *	2000-06-29	2002-01-15	Labopharm Inc.	Polymeric micelle compositions
RU2166945C1 (ru) *	2000-08-08	2001-05-20	Ефимова Лариса Степановна	Радиосенсибилизирующее вещество для лечения онкологических заболеваний
US6586460B1 (en)	2001-04-02	2003-07-01	The Board Of Regents For Oklahoma State University	Heteroarotinoids containing urea or thiourea linker
RU2192862C1 (ru) *	2001-05-23	2002-11-20	Московский научно-исследовательский институт глазных болезней им. Гельмгольца	Способ лечения больших и мультицентричных ретинобластом
AT412703B (de) *	2001-12-04	2005-06-27	Vis Vitalis Lizenz & Handels	Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
NZ521436A (en) *	2002-09-17	2005-07-29	Auckland Uniservices Ltd	DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
RU2234916C2 (ru) *	2002-10-29	2004-08-27	Московский областной научно-исследовательский клинический институт	Способ лечения онкологических больных
US7138520B2 (en) *	2003-01-13	2006-11-21	Massachusetts Institute Of Technology	Coordination complexes having tethered therapeutic agents and/or targeting moieties, and methods of making and using the same
CA2456569A1 (en) *	2003-03-14	2004-09-14	Auckland Uniservices Limited	Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
RU2243766C1 (ru) *	2003-04-01	2005-01-10	Ростовский научно-исследовательский онкологический институт МЗ РФ	Способ лечения рецидивов рака шейки матки
WO2005082867A1 (en) *	2004-03-01	2005-09-09	Auckland Uniservices Limited	Novel 1,2,4-benzotriazine-1,4-dioxides
US7989451B2 (en)	2005-03-31	2011-08-02	Auckland Uniservices Limited	Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments
CA2624707A1 (en) *	2005-10-03	2007-04-12	Genetix Pharmaceuticals, Inc.	Method for selectively depleting hypoxic cells
US20070212360A1 (en) *	2006-01-17	2007-09-13	Denko Nicholas C	Modulation of mitochondrial oxygen consumption for therapeutic purposes
US7834178B2 (en) *	2006-03-01	2010-11-16	Bristol-Myers Squibb Company	Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
JP5113038B2 (ja) *	2006-03-23	2013-01-09	テムリック株式会社	癌治療用キットおよび癌治療用医薬組成物
CA2749771C (en) *	2008-01-28	2018-05-01	Milux Holding S.A.	A drainage device comprising an active filter
CN102026634B (zh)	2008-04-10	2014-01-22	弗吉尼亚州立邦联大学	诱导肿瘤缺氧以治疗癌症
US9316632B2 (en) *	2009-03-17	2016-04-19	Marshall University Research Corporation	Methods of screening chemotherapeutic agents and treating cancer
AT511159A1 (de)	2011-02-16	2012-09-15	Selo Medical Gmbh	Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen
EP2800744A4 (de) *	2011-12-07	2015-06-03	Sri Internat Inc	Benzotriazinoxide als arzneimittel gegen mycobacterium tuberculosis
SG10201610869TA (en)	2012-06-26	2017-02-27	Del Mar Pharmaceuticals	Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
US9278124B2 (en)	2012-10-16	2016-03-08	Halozyme, Inc.	Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2983674A4 (de)	2013-04-08	2017-05-10	Dennis M. Brown	Therapeutischer nutzen suboptimal verabreichter chemischer verbindungen
BR112021018481A2 (pt)	2019-03-27	2021-11-23	Curasen Therapeutics Inc	Agonista adrenérgico beta e métodos para usar o mesmo
TW202525783A (zh) *	2019-07-01	2025-07-01	美商古拉森療法公司	β腎上腺素激動劑及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4001410A (en) *	1972-02-01	1977-01-04	Bayer Aktiengesellschaft	3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US5175287A (en) *	1986-09-25	1992-12-29	S R I International	Process for preparing 1,2,4-benzotriazine oxides
US4923878A (en) *	1988-11-14	1990-05-08	Merck & Co., Inc.	Quinolizine sulfonamides used against certain neoplastic disease states
CA2002859C (en) *	1988-11-29	1998-12-29	Jean P. F. Van Wauwe	Method of treating epithelial disorders
US5597582A (en) *	1995-09-12	1997-01-28	Sanofi	Oral gel capsule formulation of 1,2,4-benzotriazine oxides

1993
- 1993-09-22 US US08/125,609 patent/US5484612A/en not_active Expired - Lifetime
1994
- 1994-09-16 KR KR1019940023493A patent/KR100383402B1/ko not_active Expired - Fee Related
- 1994-09-19 PT PT94202693T patent/PT649658E/pt unknown
- 1994-09-19 EP EP94202693A patent/EP0649658B1/de not_active Expired - Lifetime
- 1994-09-19 PT PT99118533T patent/PT972517E/pt unknown
- 1994-09-19 DK DK94202693T patent/DK0649658T3/da active
- 1994-09-19 EP EP99118533A patent/EP0972517B1/de not_active Expired - Lifetime
- 1994-09-19 SG SG1996006227A patent/SG52568A1/en unknown
- 1994-09-19 ES ES99118533T patent/ES2224517T3/es not_active Expired - Lifetime
- 1994-09-19 ES ES94202693T patent/ES2147567T3/es not_active Expired - Lifetime
- 1994-09-19 DE DE69424915T patent/DE69424915T2/de not_active Expired - Fee Related
- 1994-09-19 AT AT99118533T patent/ATE270553T1/de not_active IP Right Cessation
- 1994-09-19 DE DE69433889T patent/DE69433889T2/de not_active Expired - Fee Related
- 1994-09-19 AT AT94202693T patent/ATE193827T1/de not_active IP Right Cessation
- 1994-09-19 DK DK99118533T patent/DK0972517T3/da active
- 1994-09-21 CA CA002132578A patent/CA2132578C/en not_active Expired - Fee Related
- 1994-09-21 UA UA94095838A patent/UA49787C2/uk unknown
- 1994-09-21 NZ NZ264502A patent/NZ264502A/en not_active IP Right Cessation
- 1994-09-21 NZ NZ299690A patent/NZ299690A/en not_active IP Right Cessation
- 1994-09-21 AU AU74117/94A patent/AU690132B2/en not_active Ceased
- 1994-09-22 CZ CZ19942326A patent/CZ289742B6/cs not_active IP Right Cessation
- 1994-09-22 IL IL111025A patent/IL111025A/en not_active IP Right Cessation
- 1994-09-22 NO NO943524A patent/NO943524L/no unknown
- 1994-09-22 JP JP6227568A patent/JPH07215882A/ja active Pending
- 1994-09-22 MY MYPI94002526A patent/MY112405A/en unknown
- 1994-09-22 RU RU94034104A patent/RU2148406C1/ru not_active IP Right Cessation
- 1994-09-22 SK SK1148-94A patent/SK282178B6/sk unknown
- 1994-09-22 HU HU9402726A patent/HUT71119A/hu unknown
1995
- 1995-05-24 US US08/448,705 patent/US5670502A/en not_active Expired - Lifetime
1997
- 1997-05-07 US US08/852,616 patent/US6121263A/en not_active Expired - Fee Related
2000
- 2000-04-26 US US09/558,786 patent/US6277835B1/en not_active Expired - Fee Related
- 2000-09-06 GR GR20000402048T patent/GR3034360T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ232694A3 (en)	1995-09-13
ES2147567T3 (es)	2000-09-16
AU7411794A (en)	1995-04-06
NZ299690A (en)	1997-11-24
DK0972517T3 (da)	2004-11-08
IL111025A0 (en)	1994-11-28
EP0649658A1 (de)	1995-04-26
EP0649658B1 (de)	2000-06-14
HU9402726D0 (en)	1994-12-28
EP0972517B1 (de)	2004-07-07
JPH07215882A (ja)	1995-08-15
DE69424915T2 (de)	2001-01-18
US5484612A (en)	1996-01-16
DK0649658T3 (da)	2000-09-11
IL111025A (en)	2006-04-10
ATE193827T1 (de)	2000-06-15
PT972517E (pt)	2004-11-30
CA2132578C (en)	1998-10-13
KR100383402B1 (ko)	2003-09-22
AU690132B2 (en)	1998-04-23
CA2132578A1 (en)	1995-03-23
RU2148406C1 (ru)	2000-05-10
ATE270553T1 (de)	2004-07-15
US5670502A (en)	1997-09-23
KR950007853A (ko)	1995-04-15
UA49787C2 (uk)	2002-10-15
MY112405A (en)	2001-06-30
NZ264502A (en)	1997-06-24
PT649658E (pt)	2000-12-29
CZ289742B6 (cs)	2002-03-13
US6277835B1 (en)	2001-08-21
NO943524L (no)	1995-03-23
HUT71119A (en)	1995-11-28
NO943524D0 (no)	1994-09-22
RU94034104A (ru)	1996-11-10
ES2224517T3 (es)	2005-03-01
SK282178B6 (sk)	2001-11-06
US6121263A (en)	2000-09-19
DE69433889D1 (de)	2004-08-12
DE69424915D1 (de)	2000-07-20
SK114894A3 (en)	1995-11-08
EP0972517A3 (de)	2000-01-26
EP0972517A2 (de)	2000-01-19
GR3034360T3 (en)	2000-12-29
DE69433889T2 (de)	2005-06-30

Publication	Publication Date	Title
HU9402726D0 (en)	1994-12-28	Method of tumor treatment
NZ280667A (en)	2000-08-25	Use of estrogen agonists for treating prostatic disease, bone loss or obesity
ATE232394T1 (de)	2003-02-15	Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
ES2100222T3 (es)	1997-06-16	Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas.
ATE260282T1 (de)	2004-03-15	Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
ATE180669T1 (de)	1999-06-15	Verwendung von pregnanderivaten zur behandlung von tumoren
DE3372764D1 (en)	1987-09-03	Pharmaceutical preparations containing (+)-cyanidan-3-ol derivatives, the use thereof, novel substituted (+)-cyanidan-3-ol derivatives, and processes for producing them
IN167848B (de)	1990-12-29
IL112963A0 (en)	1995-06-29	A pharmaceutical composition containing gamma globulins or fragments thereof
BR0110396A (pt)	2003-07-01	Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
CA2289017A1 (en)	1998-12-03	The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
PT1076561E (pt)	2005-08-31	Terapia de combinacao para o tratamento de tumores
GEP19991535B (en)	1999-03-05	Process for the Preparation of 7-Hydroxy Taxanes
EP0194164A3 (en)	1987-06-16	N-carboxyalcoyl-2-oxo-3-diaryl-5,6-triazines useful as therapeutic agents
DE69810332D1 (de)	2003-01-30	Antibakterielle carbapeneme, zusammensetzungen und verfahren zur behandlung